Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting 100 enrolled Haihe Biopharma Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.

Timeline

Start: 2022-07-27
Primary completion: 2025-10-31
Completion: 2027-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HH2853	Unknown	25 mg	Oral
Subject	HH2853	Unknown	100 mg	Oral
Subject	HH2853	Unknown	200 mg	Oral

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Summary

Timeline

Drugs

Indications